Penn Medicine's Abramson Cancer Center and the Parker Institute for Cancer Immunotherapy have renewed their partnership to advance cancer immunotherapy research.
The renewal follows the Parker Institute announcing a $125 million investment across its network to expand research efforts, according to an Aug. 21 system news release. Penn has been part of the network since its launch in 2016. The collaboration supports laboratory studies, clinical trials that study cancer immunology and training for early-career scientists.
The Parker Institute's network includes hundreds of cancer researchers and seven cancer institutions.